spironolactone has been researched along with Abnormality, Heart in 9 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy of treatment with spironolactone for congestive heart failure secondary to congenital heart disease was studied in 21 infants under 1 year of age." | 9.05 | Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease. ( Fowler, RS; Hobbins, SM; Korey, AG; Rowe, RD, 1981) |
| " We conclude that aldosterone antagonists in the dosage used had no effect on the course of postoperative hyperaldosteronism." | 5.26 | Hyperaldosteronism after heart surgery in children. Part I: Treatment with aldosterone antagonists. ( Haschke, F; Parth, K; Wimmer, M, 1981) |
| "The efficacy of treatment with spironolactone for congestive heart failure secondary to congenital heart disease was studied in 21 infants under 1 year of age." | 5.05 | Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease. ( Fowler, RS; Hobbins, SM; Korey, AG; Rowe, RD, 1981) |
| " We report successful diuretics treatment with spironolactone and furosemide at standard dose, of refractory PLE in a patient with Noonan syndrome and repaired congenital heart disease." | 3.81 | Successful diuretics treatment of protein-losing enteropathy in Noonan syndrome. ( Iemura, M; Kudo, Y; Matsuishi, T; Mizuochi, T; Seki, Y; Suda, K; Tanikawa, K; Yanagi, T; Yoshimoto, H, 2015) |
| "In children with congenital heart disease duration and extent of hyperaldosteronism and the influence of spironolactone after surgery with a heart-lung-machine, were evaluated by direct measurement of plasma aldosterone levels." | 3.66 | [The effect of aldosterone antagonists in juvenile heart surgery]. ( Holzer, H; Parth, K; Wimmer, M, 1979) |
| " We conclude that aldosterone antagonists in the dosage used had no effect on the course of postoperative hyperaldosteronism." | 1.26 | Hyperaldosteronism after heart surgery in children. Part I: Treatment with aldosterone antagonists. ( Haschke, F; Parth, K; Wimmer, M, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (55.56) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Zou, H | 1 |
| Zhang, M | 1 |
| Chen, J | 1 |
| Aniagu, S | 1 |
| Jiang, Y | 1 |
| Chen, T | 1 |
| García-Beltran, C | 1 |
| Cereijo, R | 1 |
| Quesada-López, T | 1 |
| Malpique, R | 1 |
| López-Bermejo, A | 1 |
| de Zegher, F | 1 |
| Ibáñez, L | 1 |
| Villarroya, F | 1 |
| Mizuochi, T | 1 |
| Suda, K | 1 |
| Seki, Y | 1 |
| Yanagi, T | 1 |
| Yoshimoto, H | 1 |
| Kudo, Y | 1 |
| Iemura, M | 1 |
| Tanikawa, K | 1 |
| Matsuishi, T | 1 |
| Ringel, RE | 1 |
| Peddy, SB | 1 |
| LAMBERG, BA | 1 |
| PALOHEIMO, J | 1 |
| TORSTI, P | 1 |
| Hobbins, SM | 1 |
| Fowler, RS | 1 |
| Rowe, RD | 1 |
| Korey, AG | 1 |
| Haschke, F | 1 |
| Wimmer, M | 2 |
| Parth, K | 2 |
| Holzer, H | 1 |
| Yasui, H | 1 |
2 trials available for spironolactone and Abnormality, Heart
| Article | Year |
|---|---|
Reduced circulating levels of chemokine CXCL14 in adolescent girls with polycystic ovary syndrome: normalization after insulin sensitization.
Topics: Adipocytes; Adipogenesis; Adipose Tissue, Brown; Adolescent; Arrhythmias, Cardiac; Biomarkers; Chemo | 2020 |
Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease.
Topics: Chlorothiazide; Clinical Trials as Topic; Digoxin; Drug Therapy, Combination; Female; Heart Defects, | 1981 |
7 other studies available for spironolactone and Abnormality, Heart
| Article | Year |
|---|---|
AHR-mediated DNA damage contributes to BaP-induced cardiac malformations in zebrafish.
Topics: 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide; Animals; Benzo(a)pyrene; Cytochrome P-450 CYP1A1 | 2024 |
Successful diuretics treatment of protein-losing enteropathy in Noonan syndrome.
Topics: Child; Diuretics; Female; Fontan Procedure; Furosemide; Heart Defects, Congenital; Humans; Noonan Sy | 2015 |
Effect of high-dose spironolactone on protein-losing enteropathy in patients with Fontan palliation of complex congenital heart disease.
Topics: Child; Fontan Procedure; Heart Defects, Congenital; Humans; Infant; Mineralocorticoid Receptor Antag | 2003 |
CHANGES IN THE URINARY EXCRETION OF CALCIUM AFTER INTRAVENOUS INJECTION OF ALDOSTERONE.
Topics: Aldosterone; Body Fluids; Calcium; Calcium, Dietary; Creatine; Creatinine; Heart Defects, Congenital | 1964 |
Hyperaldosteronism after heart surgery in children. Part I: Treatment with aldosterone antagonists.
Topics: Adolescent; Aldosterone; Canrenoic Acid; Child; Child, Preschool; Heart Defects, Congenital; Hematoc | 1981 |
[The effect of aldosterone antagonists in juvenile heart surgery].
Topics: Adolescent; Cardiopulmonary Bypass; Child; Child, Preschool; Drug Administration Schedule; Heart Def | 1979 |
The role of catecholamines in circulatory regulation on the chronic congestive heart failure. Clinical study of the urinary catecholamine excretion in the patients with chronic congestive heart failure.
Topics: Adolescent; Adult; Aged; Blood Pressure; Cardiomyopathies; Catecholamines; Coronary Disease; Digital | 1968 |